Why the study?
Does low-molecular-weight heparin improve clinical effect reliability and ease of administration compared to unfractionated heparin in patients undergoing routine outpatient haemodialysis?
Does low-molecular-weight heparin improve clinical effect reliability and ease of administration compared to unfractionated heparin in patients undergoing routine outpatient haemodialysis?
Low-molecular-weight heparins offer a reliable and cost-effective alternative to unfractionated heparin for anticoagulation during routine outpatient haemodialysis.
Answers are grounded in this paper and cite their sources.
Supports LMWH preference for outpatient HD in Western Europe; leaves open direct RCT comparisons versus unfractionated heparin.
Unfractionated heparin is currently the most widely used anticoagulant for outpatient haemodialysis. However, unfractionated heparin is a series of molecules, and as such has variable pharmacodynamics. Low-molecular-weight heparins were developed to improve both drug pharmacokinetic and dynamics, so to provide a reliable predictable clinical effect. The low-molecular-weight heparins are potent agents, but have an increased half-life compared with unfractionated heparin, and also require specialist laboratory monitoring. Despite these apparent drawbacks, low-molecular-weight heparins have become the anticoagulants of choice in Western Europe for routine outpatient haemodialysis sessions, due to the reliability of their clinical effect, and ease of administration, coupled with cost reduction. In standard clinical practice laboratory monitoring is not routinely performed, with drug dosing assessed by clinical inspection of the extracorporeal circuit, and the time for fistula needle sites to stop bleeding.
No takes yet. Share an insight, caveat, or question.
Andrew Davenport (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: